Health: Novo Nordisk rivals see room to compete in $100 billion weight-loss drug market gdnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gdnonline.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, May 4 (Reuters) - The enormous demand for
weight-loss treatments like Novo Nordisk's Wegovy
could support as many as 10 competing products with annual sales
reaching up to $100 billion within a decade. | 12:42pm
NEW YORK (Reuters) - The enormous demand for weight-loss treatments like Novo Nordisk's Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. More than half a dozen companies, from Pfizer Inc and Amgen Inc to smaller players like Altimmune Inc, are working on weight-loss therapies similar to Wegovy, viewing them as important future growth drivers. Novo was first to introduce an effective treatment shown to help people lose up to 15% of their weight. Eli Lilly and Co is expected to receive a U.S. weight loss approval for its similar drug, Mounjaro, later this year. | 06:22am
Stories of Las Vegas shooting victims Hannah Ahlers, Heather Alvarado, Dorene Anderson, Carrie Barnette, Jack Beaton, Denise Burditus, Sandy Casey, Thomas Day Jr., Austin Davis, Christiana Duarte, Stacee Etcheber, Keri Galvan, Dana Gardner, Angela Gomez, Charleston Hartfield and more.